{
  "id": 3464857,
  "title": "VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data",
  "url": "https://urgent.news/2026/08/26/virtus-respiratory-research-supports-development-of-apollo",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T08:00:18.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/virtus-respiratory-research-supports-development-of-apollo-therapeutics-apl-10456-from-preclinical-proof-of-concept-to-positive-phase-1-data"
  },
  "original_language": "en",
  "account": null,
  "summary": "LONDON — VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}